AGN — Algernon Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- CA$2.44m
- CA$2.08m
- 10
- 39
- 59
- 28
Annual balance sheet for Algernon Pharmaceuticals, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 6.12 | 2.41 | 1.41 | 0.125 | 0.596 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.23 | 2.29 | 0.666 | 0.096 | 0.016 |
| Prepaid Expenses | |||||
| Total Current Assets | 7.74 | 4.91 | 2.83 | 0.34 | 0.739 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 12.8 | 10.1 | 8.14 | 4.19 | 3.94 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.607 | 1.02 | 2.52 | 2.72 | 1.78 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.607 | 1.02 | 2.52 | 2.72 | 1.78 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 12.2 | 9.12 | 5.62 | 1.47 | 2.17 |
| Total Liabilities & Shareholders' Equity | 12.8 | 10.1 | 8.14 | 4.19 | 3.94 |
| Total Common Shares Outstanding |